Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MEI Pharma, Inc. MEIP
$6.95
-$0.01 (-0.14%)
На 18:00, 12 мая 2023
+115.83%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
47307584.00000000
-
week52high
13.60
-
week52low
4.00
-
Revenue
40697000
-
P/E TTM
-140
-
Beta
1.02110700
-
EPS
-4.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мая 2023 г. в 10:59
Описание компании
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Equal-Weight | Overweight | 25 мар 2022 г. |
| Truist Securities | Buy | Buy | 25 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 25 мар 2022 г. |
| BTIG | Buy | Buy | 25 мар 2022 г. |
| Jefferies | Buy | 03 февр 2022 г. | |
| Truist Securities | Hold | Buy | 06 дек 2022 г. |
| BTIG | Neutral | Buy | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Baltic Charles V. III | A | 87500 | 87500 | 05 июл 2022 г. |
| Glover Nicholas | A | 87500 | 87500 | 05 июл 2022 г. |
| DRISCOLL FREDERICK W | A | 87500 | 88 | 05 июл 2022 г. |
| GOLD DANIEL P PHD | A | 1496000 | 1496000 | 05 июл 2022 г. |
| Cohen Cheryl | A | 87500 | 87500 | 05 июл 2022 г. |
| HOWSON TAMAR D | A | 87500 | 87500 | 05 июл 2022 г. |
| Reynolds Thomas C | A | 87500 | 87500 | 05 июл 2022 г. |
| Drazba Brian G. | A | 350000 | 350000 | 05 июл 2022 г. |
| Urso David M | A | 1050000 | 1050000 | 05 июл 2022 г. |
| White Christine Anna | A | 87500 | 87500 | 05 июл 2022 г. |
Новостная лента
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
Zacks Investment Research
09 февр 2023 г. в 19:35
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
14 ноя 2022 г. в 18:48
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
Seeking Alpha
08 сент 2022 г. в 21:00
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer David Urso - Chief Operating Officer and General Counsel Richard Ghalie - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Robyn Karnauskas - Truist Yale Jen - Laidlaw & Co Nick Abbott - Wells Fargo Operator Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request.
Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
PennyStocks
17 июн 2022 г. в 16:34
Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.